Ezogabine, also known as Retigabine, is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. Ezogabine works primarily as a potassium channel opener—that is, by activating a certain family of voltage-gated potassium channels in the brain. This mechanism of action is unique among antiepileptic drugs, and may hold promise for the treatment of other neurologic conditions, including migraine, tinnitus and neuropathic pain. (Source: http://en.wikipedia.org/wiki/Retigabine). Ezogabine is discontinued (DEA controlled substance).
Zhu, Lei; Wang, Jia-le; Wang, Pu-hai. Improved synthesis of retigabine. Zhongguo Yaowu Huaxue Zazhi. Volume 24. Issue 1. Pages 31-33, 77. Journal. (2014).
Wang, Wei; Yang, Jin-lu; Zhang, Yong. Improved synthesis of retigabine. Zhongguo Xinyao Zazhi. Volume 23. Issue 2. Pages 232-234. Journal. (2014).
Kinarivala, Nihar; Patel, Ronak; Boustany, Rose-Mary; Al-Ahmad, Abraham; Trippier, Paul C. Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2). Journal of Medicinal Chemistry. Volume 60. Issue 23. Pages 9739-9756. Journal; Online Computer File. (2017).
Sudhanshu, Saxena; Jayantilal, Ranbhan Kamlesh; Kanti, Mandal Arun; Balkrishna, Sarjekar Pushpalata; Sehgal, Charanjit. A continuous green process for the preparation of alkyl (aminophenyl)carbamate. Assignee Arch Pharmalabs Limited, India. IN 2012MU00271. (2013).
Weaver, Jimmie Dean. Preparation of fluoroarenes via hydrogen bond directed photocatalytic hydrodefluorination of perfluoroarenes. Assignee The Board of Regents for Oklahoma State University, USA. WO 2018187336. (2018).
